
ASCO 2020: Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumours
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed…
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed…